Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis

Wang, Yadong; Xu, Jie; Wang, Ying; Hou, Hongjie; Shi, Li; Yang, Haiyan

doi:10.1111/ijcp.14867

Cited by 2 publications

(2 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Much has been explored about the ramifications of TB‐COVID‐19 co‐infection. The prevalence of such an occurrence was found to be minute (1.6%) among patients with COVID‐19 45 . On the other hand among patients with TB the prevalence of co‐infection was a more notable 14% 46 .…”

Section: Discussionmentioning

confidence: 95%

“…The prevalence of such an occurrence was found to be minute (1.6%) among patients with COVID‐19. 45 On the other hand among patients with TB the prevalence of co‐infection was a more notable 14%. 46 This was even more common among TB patients in this study, with 25% having experienced co‐infection possibly due to a lesser regard for COVID‐19 preventive measures.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prior COVID‐19 infection among newly diagnosed tuberculosis patients in a tertiary care center in Tehran: A case‐control study

Semnani,

Sohrabi,

Alavijeh

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveTo assess the risk of developing pulmonary tuberculosis (TB) in accordance with prior history of COVID‐19 infection.BackgroundSince the advent of the COVID‐19 pandemic much discussion has been had on the possible role it might play on global efforts to combat TB; most, focusing on the pandemic's impact on health care systems' capabilities to manage TB cases. Mechanisms have also been proposed by which the COVID‐19 infection may directly affect individuals' chance of developing TB infection. Cases have been reported with a history of COVID‐19 infection preceding a diagnosis of TB, evidencing its possible role as a risk factor for the disease.MethodsA case‐control study was conducted enrolling patients diagnosed with pulmonary TB in the absence of major risk factors previous history of TB, (HIV) human immunodeficiency virus infection), end‐stage renal disease, organ transplants, and use of immunosuppressive agents) for developing TB. Each patient was age and sex matched with one healthy control. Data regarding prior COVID‐19 infection, diabetes, and smoking status as well as the use of corticosteroids and Tocilizumab for the treatment of COVID‐19 infection was obtained. Bivariate analysis was conducted and variables with a likely association with TB status were entered in a multivariate model.ResultsBivariate analysis demonstrated a significant relationship between prior COVID‐19 infection and TB (95% confidence interval = 1.1−22.8, odds ratio [OR] = 5). Among other variables the severity of COVID‐19 infection was found to have a likely association with TB status (p = .125). In a multivariate model, prior COVID‐19 infection per se, was not found to be significantly associated with TB (p = .12, OR = 4.5).ConclusionsThere seems to be an association between prior history of COVID‐19 and a future diagnosis of TB partially linked to the severity of disease. The findings of the current study may serve as a basis for further studies to determine the need for and efficacy of measures to follow‐up COVID‐19 patients at an increased risk for developing TB.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Prior COVID‐19 infection among newly diagnosed tuberculosis patients in a tertiary care center in Tehran: A case‐control study

Semnani,

Sohrabi,

Alavijeh

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

Clinical features and effectiveness of treatment of patients with pulmonary tuberculosis who have had COVID-19

Zakharov,

Chernykh,

Amansakhedov

et al. 2023

Vrach

View full text Add to dashboard Cite

In May 2023, WHO officially declared the end of the COVID-19 pandemic. Assessing the consequences of the pandemic remains scientifically and practically relevant. Patients who have recovered from COVID-19 are at risk of developing or relapsing tuberculosis (TB). A comparative retrospective-prospective study was conducted on 88 patients with pulmonary TB, including 45 patients after COVID-19. In 68.9% of those examined, COVID-19 was mild. Tuberculomas and focal pulmonary TB predominated in patients. Tuberculomas and focal pulmonary TB predominated in patients. The most common patterns on CT scans were ground-glass and severe changes. Among laboratory parameters, increases in fibrinogen, D-dimer, and C-reactive protein were more often observed. COVID-19, which was mostly mild, did not have a significant impact on the effectiveness of treatment for TB patients. At the same time, such patients had a more frequent development of adverse reactions during anti-tuberculosis chemotherapy and a complicated course of pulmonary TB.

show abstract

Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis

Cited by 2 publications

References 121 publications

Prior COVID‐19 infection among newly diagnosed tuberculosis patients in a tertiary care center in Tehran: A case‐control study

Prior COVID‐19 infection among newly diagnosed tuberculosis patients in a tertiary care center in Tehran: A case‐control study

Clinical features and effectiveness of treatment of patients with pulmonary tuberculosis who have had COVID-19

Contact Info

Product

Resources

About